| Literature DB >> 31010562 |
Melanie A McNally1, Janet S Soul2.
Abstract
Neonatal brain injury (NBI) remains a major contributor to neonatal mortality and long-term neurodevelopmental morbidity. Although therapeutic hypothermia is the only proven treatment to minimize brain injury caused by neonatal encephalopathy in term neonates, it provides incomplete neuroprotection. There are no specific drugs yet proven to prevent NBI in preterm neonates. This review discusses the scientific and emerging clinical trial data for several neuroprotective drugs in development, examining potential efficacy and safety concerns. Drugs with the highest likelihood of success and closest to clinical application include erythropoietin for term and preterm neonates and antenatal magnesium for preterm neonates.Entities:
Keywords: Erythropoietin; Hypoxic-ischemic encephalopathy; Magnesium; Neonatal brain injury; Neuroprotection; Periventricular leukomalacia; Therapeutic hypothermia
Year: 2019 PMID: 31010562 DOI: 10.1016/j.clp.2019.02.006
Source DB: PubMed Journal: Clin Perinatol ISSN: 0095-5108 Impact factor: 3.430